Home › Compare › ORGJF vs ABBV
ORGJF yields 1.09% · ABBV yields 3.06%● Live data
📍 ORGJF pulled ahead of the other in Year 6
Combined, ORGJF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ORGJF + ABBV for your $10,000?
Organo Corporation operates as a water treatment engineering company in Japan and internationally. The company operates through two segments, Water Treatment Engineering Business Unit and Performance Products Business Unit. It offers pure water systems, such as reverse osmosis (RO) systems, regenerative automatic and manual pure water systems, electric regeneration pure water systems, desktop-type pure water systems, cabinet-type pure water systems, electrode ionization high-purity water systems, cartridge water purifiers, and two-stage RO systems; ultrapure water systems, including desktop and cabinet-type ultrapure water systems, and final polishing unit; and other equipment comprising alkaline electrolyzed water production equipment, homogenizers, electro conductivity meters, resistivity meters, and ion exchange filters. The company also provides water, wastewater, and RO water treatment chemicals; industrial filters consisting of micro filter, sanitary, polypropylene, and plastic housings, as well as micro, RO wound, PF cartridge, capsule, and PF carbon; and commercial water purifiers. In addition, it offers ultrapure and multi-functional water production systems, wastewater treatment systems, valuable resource recovery systems, and organic solvent refining systems for the electronics industry; water supply and sewage treatment facilities; purified water production and supply systems, UF water production and supply systems, and water for injection production and supply systems, as well as pharmaceutical water system consulting services; condensate filter, condensate demineralizer, reactor water cleanup, fuel pool cleanup, makeup water, and waste water treatment systems; and sugar refining systems and equipment. The company was formerly known as Japan Organo Co., Ltd. and changed its name to Organo Corporation in 1966. Organo Corporation was incorporated in 1941 and is headquartered in Tokyo, Japan.
Full ORGJF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.